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Over a 20-year period, 34 patients with FIG0 stage II ovarian carcinoma were treated 
with postoperative pelvic irradiation at the University of Michigan. Complications of radiation 
treatment were minimal. The overall actuarial disease-free Syear survival was 53%. This 
was not significantly different for substages IIA, IIB, or IIC. Patients with well-differentiated 
tumors had a significantly better survival than patients with moderate or poorly differentiated 
tumors (P < 0.05). The implications for managing stage II ovarian carcinoma are discussed. 
0 1988 Academic Press, Inc. 
INTRODUCTION 
Despite recent developments in the management of ovarian cancer, overall 
survival remains poor. Part of the reason for the low cure rate is that the majority 
of patients present with advanced stage disease. However, the recurrence risk 
even for patients with localized disease remains high. FIG0 (International Fed- 
eration of Gynecology and Obstetrics) stage II ovarian cancer is defined as growth 
involving one or both ovaries with pelvic extension. When managed by surgery 
alone the recurrence risk for stage II ovarian cancer is over 80% [l-3]. While 
it is clear that an initial optimal cytoreduction is important as primary treatment, 
ideal postoperative adjuvant therapy remains controversial [4,5]. This study was 
undertaken to review the 20-year experience at the University of Michigan Hospital 
in using postoperative pelvic irradiation in FIG0 stage II ovarian carcinoma. 
MATERIALS AND METHODS 
Between January 1, 1961, and January 1, 1981, there were 38 patients treated 
for stage II carcinoma of the ovary at the University of Michigan Hosptial (see 
Table 1). All patients underwent an initial laparotomy for removal of the tumor; 
staging was based on findings at the time of the initial surgery. Twenty-eight of 
these patients had their initial operation performed at the University of Michigan; 
10 patients had their initial operation performed at outside institutions and were 
subsequently referred for further management. Histologic sections on all patients 
were reviewed by a pathologist at the University of Michigan and all patients 
were presented for discussion at the Gynecology Tumor Conference. Three 
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TABLE 1 





Growth involving one or both ovaries with pelvic extension 
Extension and/or metastases to the uterus and/or tubes 
Extension to other pelvic tissues 
Tumor either stage IIA or IIB, but with tumor on the surface of one or both 
ovaries; or with capsule(s) ruptured; or with ascites present containing 
malignant cells; or with positive peritoneal washings 
patients received postoperative chemotherapy without radiation. One patient 
refused any adjuvant treatment. The remaining 34 patients all received postoperative 
pelvic irradiation. A retrospective review of the clinical course of these 34 patients 
forms the basis for the present study. 
External pelvic irradiation was administered by the University of Michigan 
Radiation Therapy Department by a cobalt-60 machine. Anterior and posterior 
parallel opposed fields of 15 by 16 cm were utilized; a total midplane dose of 
approximately 5000 rad was administered in 5 to 6 weeks. All patients completed 
treatment without interruption. One patient also received a preoperative radium 
implant because of a separate primary adenocarcinoma of the endometrium. 
Seven patients received Chlorambucil, 6 to 10 mg per day for 12 to 24 months 
following radiation therapy. 
The ages of the patients ranged from 28 to 74 years with a mean of 52.3 years. 
All patients underwent a laparotomy to resect the primary tumor. In 29 patients 
an optimal cytoreduction was achieved (largest residual tumor less than 1.5 cm 
in diameter). A hysterectomy was performed in 24 patients and an omentectomy 
was performed in 7 patients. All patients underwent careful evaluation of the 
abdomen by inspection and palpation; however, it was generally not the practice 
during this period to carry out a complete staging procedure with retroperitoneal 
lymph node biopsies, omentectomy, subdiaphragmatic washings, etc. 
The predominant types of ovarian cancer were epithelial in nature (see Table 
2). The minimum follow-up for all patients was 5 years. No patient was lost to 
follow-up; four patients died of intercurrent causes during the 5-year period. x’ 
analysis was used as a test of statistical significance. 
RESULTS 
The actuarial disease-free 5-year survival for 34 patients with stage II carcinoma 
of the ovary undergoing postoperative pelvic irradiation was 53%. The survival 
in patients dying of their disease ranged from 9 to 72 months with a median of 
25 months. When evaluated by substage the results are noted in Table 3. The 
disease-free 5-year survivals were 60% for stage IIA, 52% for stage IIB, and 
52% for stage IIC. There was no significant difference in survival by substage. 
Patients with weIl-differentiated tumors had a significantly better outcome than 
patients with moderate or poorly differentiated tumors. Disease-free survivals at 
5-years were 78 and 30%, respectively (P < 0.05). 
28 TERADA, MORLEY, AND ROBERTS 
TABLE 2 
HISTOLOGY OF STAGE II OVARIAN CANCERS 



















Of the five patients who underwent suboptimal cytoreduction at the time of 
their initial surgery (residual tumor greater than 1.5 cm in diameter) only one 
patient (20%) was alive and free of disease at 5 years. Five-year survival was 
56% for optimally resected patients; this difference was not statistically significant. 
In seven patients omentectomy and cytologic washings were performed; two 
patients also underwent pelvic and periaortic lymph node biopsies. Five-year 
survival for this optimally staged group was 46%. 
The survival in seven patients who underwent additional primary treatment 
with Chlorambucil was not significantly different; there were three of seven 
patients (43%) alive and free of disease at 5 years. 
The complications of postoperative pelvic irradiation were primarily of a minor 
nature (see Table 4). Twelve patients (32%) were treated symptomatically for 
complaints of nausea, diarrhea, bladder irritation, or skin erythema. One patient 
(3%) developed radiation enteritis with weight loss and intermittent episodes of 
a low grade bowel obstruction which responded to conservative management. 
There were no fistula complications and no patients required laprotomy for bowel 
complications. 
TABLE 3 
FOLLOW-UP IN PATIENTS WITH STAGE II OVARIAN CANCER AT 5 YEARS 
FIG0 substage A/NED A/WD D/WD D/ICD Total 
IIA 3 0 2 0 5 
IIB 6 1 5 I 13 
IIC 6 0 7 3 16 
Total 1.5 1 14 4 34 
Note. A/NED, alive/no evidence of disease; A/WD, alive/with disease; DIWD, dead/this cancer 
present at death; D/ICD, dead/of intercurrent causes. 
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TABLE 4 
COMPLICATIONS OF RADIOTHERAPY IN 34 
















Ovarian carcinoma is defined as stage II when tumor has spread beyond the 
ovaries, but remains confined to the pelvis. Although the cancer remains localized, 
survival rates are still poor. When surgery alone is utilized, long-term survival 
rates of less than 20% are obtained [l-3]. In the present series, postoperative 
pelvic irradiation resulted in a disease-free 5-year survival of 53%. 
Pelvic irradiation, however, fails to achieve long-term survival in a significant 
proportion of patients. One must consider the possibility of subclinical metastasis 
to the upper abdomen at the time of diagnosis. It was generally not the practice 
during most of the period of this study to perform complete staging procedures. 
Piver et al. have indicated that over 20% of patients diagnosed as having stage 
I and II ovarian cancer may be understaged at the time of surgery [6]. This 
clearly impacts upon survival. When sites of recurrence are noted following 
pelvic radiotherapy, the majority occur in the abdomen as well as in the pelvis 
[7,8]. Therefore, with stage II ovarian cancer, a careful surgical evaluation of 
the omentum, retroperitoneal nodes, bowel mesentery, and subdiaphragmatic 
area is crucial. 
Dembo et al. [9] compared the results of using pelvic irradiation, pelvic plus 
whole abdomen irradiation, and pelvic irradiation plus Chlorambucil. For the 
combined group of Stage IB and II ovarian carcinoma the relapse-free survival 
at 5 years was 82% for patients receiving abdominopelvic irradiation, 52% for 
patients receiving pelvic irradiation plus Cholrambucil, and 50% for patients 
receiving pelvic irradiation alone. Therefore, abdominopelvic irradiation improves 
survival over pelvic irradiation alone or pelvic irradiation combined with Chlor- 
ambucil. The complications of abdominopelvic irradiation, however, may be 
significant. Fuks [3] noted that 78% of patients subjected to abdominal irradiation 
developed acute morbidity manifested by diarrhea, nausea, vomiting, and weight 
loss; 14% developed intestinal obstruction requiring laparotomy. 
As an alternative to abdominal irradiation, some authors have recommended 
the intraperitoneal instillation of radiocolloids [2,5,10]. Pezner et al. [5] reports 
utilizing 15.0 mCi of P3* combined with 4000 rad pelvic irradiation. With this 
regimen there was a 67% 5-year survival in patients with stages IIA and IIB 
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with no gross residual tumor. However, with gross residual tumor left at the 
time of surgery, 5-year survival was only 25% for stage IIB carcinoma. When 
external pelvic and intraperitoneal radiotherapy are combined, however, major 
bowel complications may occur in over 20% of patients [11,12]. Therefore, this 
particular combination may not provide a significant advantage in improving 
survival or reducing the risk of complications. 
The role of chemotherapy in Stage II ovarian cancer is not clear. In the present 
study the addition of Chlorambucil did not improve results when compared to 
pelvic irradiation alone. Smith et al. [13] randomized patients with stages I, II, 
and III ovarian cancer between abdominopelvic irradiation versus Melphalan. 
Five-year survivals for stage II patients were 67% in the radiation group versus 
73% in the Melphalan group. Other studies comparing postoperative radiation 
with postoperative combination chemotherapy have found no significant difference 
in survival between the two groups [14,15]. Therefore postoperative adjuvant 
chemotherapy may be an effective alternative to radiotherapy in stage II ovarian 
carcinoma. 
In summary, pelvic irradiation may be utilized as adjuvant therapy in patients 
with stage II ovarian carcinoma. A significant porportion of patients, however, 
may relapse following treatment; histologic grade may be of some benefit in 
predicting which patients will remain free of disease [161. Patients that are in- 
completely staged may have subclinical stage III disease at the time of diagnosis 
and may be at particularly high risk for recurrence. Consideration should be 
given to treating these patients with chemotherapy or abdominopelvic radiotherapy. 
The initial surgical approach, therefore, should include an optimal resection of 
tumor in conjunction with a thorough exploration of the abdomen with multiple 
biopsies. The form of adjuvant treatment yielding optimal results remains undefined. 
An overall 5-year survival of 53% indicates a limited efficacy when pelvic irradiation 
is used as the primary mode of adjuvant therapy following surgery. 
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